Cyclacel Pharmaceuticals Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cyclacel Pharmaceuticals stock.
View analyst ratings for Cyclacel Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Cyclacel Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cyclacel Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cyclacel Pharmaceuticals saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 796,400 shares, an increase of 22.1% from the June 15th total of 652,200 shares. Based on an average trading volume of 117,100 shares, the short-interest ratio is currently 6.8 days. Currently, 10.7% of the shares of the company are short sold.
View Cyclacel Pharmaceuticals' Short Interest.

Cyclacel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its earnings results on Wednesday, May, 12th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.05.
View Cyclacel Pharmaceuticals' earnings history.

Cyclacel Pharmaceuticals' stock was trading at $0.5399 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CYCC stock has increased by 826.1% and is now trading at $5.00.
View which stocks have been most impacted by COVID-19.

Cyclacel Pharmaceuticals shares reverse split before market open on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 14th 2020. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 5 shares after the split.

1 Wall Street analysts have issued 12 month target prices for Cyclacel Pharmaceuticals' stock. Their forecasts range from $17.00 to $17.00. On average, they expect Cyclacel Pharmaceuticals' share price to reach $17.00 in the next year. This suggests a possible upside of 240.0% from the stock's current price.
View analysts' price targets for Cyclacel Pharmaceuticals or view top-rated stocks among Wall Street analysts.

1 employees have rated Cyclacel Pharmaceuticals CEO Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among Cyclacel Pharmaceuticals' employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Cyclacel Pharmaceuticals include Zynerba Pharmaceuticals (ZYNE), Terns Pharmaceuticals (TERN), Immunome (IMNM), MediciNova (MNOV), AVEO Pharmaceuticals (AVEO), Chemomab Therapeutics (CMMB), Biofrontera (BFRA), Decibel Therapeutics (DBTX), Galectin Therapeutics (GALT), Mereo BioPharma Group (MREO), Aptinyx (APTX), Corbus Pharmaceuticals (CRBP), Marker Therapeutics (MRKR), Equillium (EQ) and Gemini Therapeutics (GMTX).
View all of CYCC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

Cyclacel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include NEXT Financial Group Inc (0.09%).
View institutional ownership trends for Cyclacel Pharmaceuticals.

CYCC stock was bought by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc.
View insider buying and selling activity for Cyclacel Pharmaceuticals or or view top insider-buying stocks.

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYCC stock can currently be purchased for approximately $5.00.

Cyclacel Pharmaceuticals has a market capitalization of $46.17 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-8,440,000.00 in net income (profit) each year or ($3.87) on an earnings per share basis.

Cyclacel Pharmaceuticals employs 12 workers across the globe.

The official website for Cyclacel Pharmaceuticals is www.cyclacel.com.

Cyclacel Pharmaceuticals is headquartered at 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922.

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected]